Somapacitan-beco
HealthData.Gov
Updated Oct 29, 2026
About this dataset
Sogroya (generic: somapacitan-beco) is a prescription injection solution made by Novo Nordisk for subcutaneous use. It contains somapacitan at 3.3 mg/mL strength and was approved under BLA761156, with marketing starting in May 2023. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Somapacitan-beco
Access the FDA dataset for Somapacitan-beco — ANDA 761156 submitted by Mylan Institutional LLC
Modified Apr 29, 2026